Is Aravive, Inc. (ARAV) a Buy, Sell, or Hold?
NASDAQ : ARAV
Aravive, Inc.
$0.0401 USD
-$0.01 (-13.39%)
- Volume
- 4.04M
- Average Volume
- 2.16M
- Market Capitalization
- $2.95M
- P/E Ratio
- -0.02
- Dividend Yield
- 0.00%
- Price Target
- $0.25
- Year High
- $2.46
- Year Low
- $0.04
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.73
Company Overview
NASDAQ
Fredric N. Eshelman
Biotechnology
Healthcare
ARAV
23
US
USD
Liquidity Metrics
0.59
2.73
2.83
2.61
0.00
Sales & Valuation
$9.14M
0.32
0.14
-0.05
-1.79
Profitability
-$2.22
-$80.92M
-885.64%
-835.31%
-306.06%
-130.20%
P/E Metrics
-0.02
0.00
0.00
Analyst Price Target & Rating
$0.25
$0.25
$0.25
0/5
18 Analysts
-83.96%
Financial Health Scores
-90.45
4/9
-$215K
$13.05M
$11.35M
-$94.37M
Key Metrics (TTM)
-$44.47M
-4.87
0.63
2.73
-306.06%
-161.69%
-5548.17%
-2206.55%
-55 days
Company Executives
| Name | Title |
|---|---|
| Jeffrey L. Cleland | Co-Founder |
| Joshua Aaron Silverman | Co-Founder |
| Marek Ciszewski | Vice President of Investor Relations |
| Fredric N. Eshelman | Executive Chairman |
Poll Results
No votes yet today — be the first to share your view!
About Aravive, Inc. (NASDAQ:ARAV) Stock
Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston, Texas, dedicated to discovering and developing innovative treatments for life-threatening illnesses such as cancer and fibrosis. The company's primary therapeutic candidate, batiraxcept, is an ultrahigh-affinity decoy protein engineered to disrupt the GAS6-AXL signaling pathway. This drug is currently progressing through a Phase III clinical trial for platinum-resistant recurrent ovarian cancer, and is also being evaluated in Phase Ib/II studies for clear cell renal cell carcinoma and pancreatic adenocarcinoma. Aravive also has AVB-S6 in its pipeline, a soluble Fc-fusion protein aimed at blocking the activation of the same GAS6-AXL pathway. Beyond internal development, Aravive has forged strategic partnerships. ... This includes a collaboration with WuXi Biologics (Hong Kong) Limited to develop novel, high-affinity bispecific antibodies targeting cancer and fibrosis. Furthermore, a license agreement with 3D Medicines Inc. grants rights to develop and commercialize products featuring batiraxcept as the sole active ingredient for human oncological diseases across mainland China, Taiwan, Hong Kong, and Macau. Originally incorporated in 2008 as Versartis, Inc., the company adopted the name Aravive, Inc. in October 2018.
Frequently Asked Questions
-
What is the current Aravive, Inc. (ARAV) stock price?
-
Aravive, Inc.(NASDAQ:ARAV) stock price is $0.0401 in the last trading session. During the trading session, ARAV stock reached the peak price of $2.46 while $0.04 was the lowest point it dropped to. The percentage change in ARAV stock occurred in the recent session was --13.39% while the dollar amount for the price change in ARAV stock was -$0.01.
-
ARAV's industry and sector of operation?
-
The NASDAQ listed ARAV is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ARAV?
-
Jeffrey L. Cleland | Co-Founder
Joshua Aaron Silverman | Co-Founder
Marek Ciszewski | Vice President of Investor Relations
Fredric N. Eshelman | Executive Chairman
| -
How many employees does ARAV have?
-
Number of ARAV employees currently stands at 23. ARAV operates from River Oaks Tower, Houston, TX 77098, US.
-
Link for ARAV official website?
-
Official Website of ARAV is: https://aravive.com
-
How do I contact ARAV?
-
ARAV could be contacted at phone #936 355 1910 and can also be accessed through its website. ARAV operates from River Oaks Tower, Houston, TX 77098, US.
-
How many shares of ARAV are traded daily?
-
The average number of ARAV shares traded daily for last 3 months was 2.16M.
-
What is the market cap of ARAV currently?
-
The market value of ARAV currently stands at $2.95M with its latest stock price at $0.0401